These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9624540)

  • 1. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
    Souli M; Wennersten CB; Eliopoulos GM
    Int J Antimicrob Agents; 1998 Apr; 10(1):23-30. PubMed ID: 9624540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
    Loza E; Morosini M; Negri MC; Almaraz F; Cantón R; Baquero F
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2786-9. PubMed ID: 9420061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
    Biedenbach DJ; Barrett MS; Croco MA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
    Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
    Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
    Klugman KP; Capper T
    J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
    Dorai-John T; Thomson CJ; Amyes SG
    J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
    Esposito S; Noviello S; Ianniello F
    Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of moxifloxacin(BAY 12-8039) against respiratory tract pathogens from six Latin-American countries.
    Cardeñosa G O; Soto-Hernández JL
    Chemotherapy; 2000; 46(6):379-82. PubMed ID: 11053902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S; Noviello S; Ianniello F
    J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.
    Spangler SK; Jacobs MR; Appelbaum PC
    Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):965-7. PubMed ID: 8187796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens.
    Sefton AM; Maskell JP; Seymour AC; Minassian M; Williams JD
    J Antimicrob Chemother; 1996 Apr; 37(4):803-8. PubMed ID: 8722546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.
    Bryan JP; Waters C; Sheffield J; Wagner KF
    Eur J Clin Microbiol Infect Dis; 1990 May; 9(5):361-5. PubMed ID: 2142647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
    Blondeau JM; Vaughan D; Laskowski R; Borsos S;
    Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.